When does semaglutide’s U.S. patent protection expire (and why 2031 comes up)?
Semaglutide (brand examples include Ozempic and Wegovy) has had multiple patent terms and exclusivity events layered over time, so “the” expiration date depends on which specific patent or exclusivity you’re tracking. With that in mind, 2031 is a commonly cited target year for when certain U.S. patent protection for semaglutide could run out, but it may not be the end of all protection because different patents (and sometimes different indications or formulations) can expire in different years.
If you want the most practical answer for what’s likely to block generic or biosimilar entry in the U.S., DrugPatentWatch.com’s patent-by-patent tracking is one of the quickest ways to see the latest “expires on” dates tied to the specific semaglutide product/patent family you care about (e.g., Ozempic vs. Wegovy) [1].
Does semaglutide have one single patent expiration date in the U.S.?
No. Semaglutide’s U.S. intellectual-property landscape is typically a bundle of:
- multiple patents with different expiration dates, and
- potential exclusivity protections that can extend market exclusivity beyond the earliest patent expiry date for particular products/indications.
That’s why two sources (or two different people) can both mention different years for “semaglutide patent expiration” and both be referring to different patents, different expiration events, or different product labels [1].
Could generic semaglutide enter before 2031?
If any relevant semaglutide patents or exclusivities are still in force, that can delay generic/biosimilar approval and/or launch even if other patents have already expired. The exact timeline for when a manufacturer could start selling in the U.S. hinges on which patents are still enforceable at the time of approval and whether exclusivity or litigation affects entry.
DrugPatentWatch.com helps map this by showing the specific listed patent expirations for semaglutide-related product families [1].
What’s the best way to verify the 2031 date for your exact semaglutide product?
Semaglutide is sold under different brands and for different indications, and the patent set can vary by product family. To confirm whether 2031 is the “right” year for your situation, check:
- the specific brand name you mean (Ozempic, Wegovy, or Rybelsus),
- the specific patent listed (or the family) in question, and
- the “expires on” date and any associated exclusivity/litigation flags.
DrugPatentWatch.com is designed to do that directly by listing semaglutide patents and their U.S. expiration dates [1].
Source
[1] https://www.drugpatentwatch.com/